Recent Updates
Recently added Catalysts
GUTS Positive Sentiment

Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference

Key Takeaway: Fractyl Health, a company specializing in metabolic therapeutics, will participate in the 8th Annual Evercore Healthcare Conference. CEO Harith Rajagopalan will engage in a fireside chat on December 3, 2025. The conference aims to address the growing issues of obesity and type 2 diabetes, highlighting Fractyl's commitment to innovative treatment approaches.
Price reaction · baseline $1.57 (2025-11-28 close) · hit pre-market · 1 other GUTS headline(s) in the window, move may be shared
day 0 close
-0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Fractyl Health is participating in a significant healthcare conference.
  • The company focuses on innovative treatments for obesity and type 2 diabetes.
  • Fractyl has a strong intellectual property portfolio with numerous patents.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+132%
120-day peak, hindsight
Typical move
6.6%
average across 5 past catalysts
Cash runway
~9 mo
Medium dilution risk

Full Press Release Details

BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in a fireside chat at the 8thAnnual Evercore Healthcare Conference, being held December 2-4, 2025, in Coral Gables, FL.

8thAnnual Evercore Conference

Format: Fireside chat and one-on-one meetings
Date: 12/03/2025
Time: 1:45 PM ET
A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website athttps://ir.fractyl.com/
About Fractyl HealthFractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. The Company has a robust and growing IP portfolio, with 33 granted U.S. patents and approximately 45 pending U.S. applications, along with numerous foreign issued patents and pending applications. Fractyl is based in Burlington, MA. For more information, visitwww.fractyl.com.

Frequently Asked Questions

When is Fractyl Health participating in the conference?

Fractyl Health will participate in the conference from December 2-4, 2025.

Who will represent Fractyl Health at the conference?

Harith Rajagopalan, M.D., Ph.D., will represent Fractyl Health.

What is the focus of Fractyl Health's work?

Fractyl Health focuses on treating obesity and type 2 diabetes.

How many patents does Fractyl Health hold?

Fractyl Health has 33 granted U.S. patents and about 45 pending applications.

Last updated: Dec 1, 2025